Therapy News and Research

RSS

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals.

18 Nov 2013

Measuring BMI can help predict diabetic patient's risk for heart disease

Researchers from the Intermountain Medical Center Heart Institute, in collaboration with researchers from Johns Hopkins University and the National Institutes of Health, have discovered a simple way to further predict a diabetic patient's risk for heart disease: by measuring their body mass index or BMI.

17 Nov 2013

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Arvin Dar, PhD, structural and chemical biologist in oncological sciences at the Icahn School of Medicine at Mount Sinai, is one of 41 national recipients of the prestigious National Institutes of Health (NIH) Director's New Innovator Awards for High-Risk, High Reward Research. The award will support Dar's research into Ras-dependent cancers, specifically investigating how to combat mutations in Ras, a protein implicated in at least one of every five cancers.

16 Nov 2013

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression

Successful gene therapy is based on the effective delivery and maintained expression of healthy copies of a gene into tissues of individuals with a disease-associated genetic mutation.

16 Nov 2013

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

The results of the Home Monitoring of the Eye (HOME) study, conducted in Age-Related Eye Disease Study 2 (AREDS2) clinical centers, executed by the EMMES Corporation and sponsored by Notal Vision Ltd. Tel Aviv, Israel, have been accepted for publication in Ophthalmology.

16 Nov 2013

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Oraya® Therapeutics, Inc. announced today that initial three-year safety follow-up data from its INTREPID study of Oraya Therapy™ stereotactic radiotherapy for the treatment of wet age-related macular degeneration (AMD) were presented for the first time today during the America Academy of Ophthalmology's (AAO) annual meeting in New Orleans.

16 Nov 2013

Reengineered protein may lead to safer, more effective retroviral gene therapy

A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus (MLV) replication may lead to safer, more effective retroviral gene therapy.

16 Nov 2013

Scientists join patients to address Friedreich's Ataxia

The Spanish Federation of Ataxia (FEDAES)—in representation of the GENEFA Platform for a Friedreich's Ataxia cure—, the Babel Family association for biomedical research into Friedreich's Ataxia, the "Centro de Biología Molecular Severo Ochoa" (CMBSO), and the Institute for Research in Biomedicine (IRB Barcelona) have signed an agreement through which these patients' associations will fund, by means of donations, a 3-year research project addressing Friedreich's Ataxia.

16 Nov 2013

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

An interim study by Italian researchers showed that using a modelling programme together with IPSS and dosage measure can predict the severity of acute urinary symptoms in patients with early prostate cancer who underwent radiotherapy.

16 Nov 2013

Bleach solution could provide new way to treat skin damage

Processes that age and damage skin are impeded by dilute bleach solution, according to a new study by researchers at the Stanford University School of Medicine.

16 Nov 2013

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

Combining the drug gemtuzumab ozogamicin with conventional chemotherapy may improve the outcome of bone marrow transplantation for some children battling high-risk acute myeloid leukemia, according to a study led by St. Jude Children's Research Hospital. The results appear in the current edition of the journal Cancer.

16 Nov 2013

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

Edith Sanford Breast Cancer (ESBC), part of the Sanford Health system based in Sioux Falls, SD, today announced it is partnering with the Athena Breast Health Network, a University of California program, to advance the use of a personalized breast cancer risk assessment.

16 Nov 2013

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that its wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co., Ltd., has entered into a supply arrangement with Pharmacyclics, Inc.

15 Nov 2013

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

Zafgen, Inc., a leading biopharmaceutical company dedicated to addressing the unmet needs of severely obese patients, today announced final efficacy and safety data from its recently completed Phase 2 study of beloranib, a selective inhibitor of methionine aminopeptidase 2.

15 Nov 2013

New cholesterol guidelines represent the biggest change in more than 25 years

New cholesterol guidelines for identifying adults at risk for heart disease represent the biggest change in such expert advice in more than 25 years, according to Loyola University Health System preventive cardiology experts.

15 Nov 2013

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

A novel combination anti-psoriasis therapy has potential for superior and longer-lasting therapeutic effects than current topical treatments by targeting genetic abnormalities in deeper layers of the skin. This research is being presented at the 2013 American Association of Pharmaceutical Scientists Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in San Antonio, Nov. 10-14.

15 Nov 2013

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Vanda Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee voted overwhelmingly to recommend the approval of Vanda's New Drug Application for tasimelteon, proposed tradename HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

15 Nov 2013

Copper intake via food and water can accelerate growth of tumors

Copper imbalances have been associated with a number of pathological conditions, including cancer. Publishing in PNAS scientists at EPFL have found that copper in drinking water - given at the maximum levels permitted in public water supplies - accelerated the growth of tumors in mice. On the other hand, reducing copper levels reduced tumor growth.

15 Nov 2013

Medical researchers discover structure of potential drug target for rare genetic disease

Medical researchers at the University of Alberta have discovered the structure of a potential drug target for a rare genetic disease, paving the way for an alternative treatment for the condition.

15 Nov 2013

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer's disease psychosis.

15 Nov 2013

Therapy News and Research

Eisai partners with NewBridge Pharmaceuticals to market Halaven drug in Middle East

Measuring BMI can help predict diabetic patient's risk for heart disease

Mount Sinai biologist wins NIH Director's New Innovator Awards for High-Risk, High Reward Research

Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression

Study shows patients at high-risk of CNV benefit from ForeseeHome device for earlier detection

Oraya presents data from INTREPID study of stereotactic radiotherapy for treatment of wet AMD

Reengineered protein may lead to safer, more effective retroviral gene therapy

Scientists join patients to address Friedreich's Ataxia

Quantitative models predict risk of acute urinary symptoms in prostate cancer patients treated with RT

Bleach solution could provide new way to treat skin damage

GO drug may improve outcome of bone marrow transplantation for select pediatric leukemia patients

ESBC joins with Athena Breast Health Network to advance personalized breast cancer risk assessment

WuXi PharmaTech subsidiary enters into supply arrangement with Pharmacyclics

Zafgen presents safety, efficacy data from beloranib Phase 2 study at Obesity Week 2013

New cholesterol guidelines represent the biggest change in more than 25 years

Novel combination anti-psoriasis therapy targets genetic abnormalities in deeper layers of the skin

FDA Advisory Committee votes in favor of Vanda's tasimelteon NDA for Non-24-Hour Disorder

Copper intake via food and water can accelerate growth of tumors

Medical researchers discover structure of potential drug target for rare genetic disease

ACADIA Pharmaceuticals initiates pimavanserin Phase II trial in ADP patients

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News